Last checked at 30 Nov 2017 15:54
30 November 2017 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces it was notified on 27 November 2017 that Chris Meredith, who is a Director and PDMR, following the end of the holding period, has exercised 22,203 options from the Deferred Annual Bonus Plan (DAB). Mr Meredith elected to receive an additional 296 dividend shares which were earned during the 3 year holding period under the terms of this scheme. Mr Meredith subsequently sold 10,726 Ordinary Shares of 5p each on 27 November 2017 at a share price of 312.109p per Ordinary Share to cover the tax and National Insurance payable on this exercise.
As a result of these transactions Chris Meredith's beneficial interest in the Company has increased from 1,470,306 shares to 1,482,079 shares.
Deferred Annual Bonus Plan (DAB)
Director | DABs prior to exercise | DABs exercised | Dividend Shares received | Ordinary Shares sold | Ordinary Shares retained | DABs after exercise |
Chris Meredith, Chief Executive Officer | 105,587 | 22,203 | 296 | 10,726 | 11,773 | 83,384 |
Overall Holding
Director | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Chris Meredith, Chief Executive Officer | 1,470,306 | 22,203 | 296 | 10,726 | 312.109p | 1,482,079 | 0.7% |
The Company further announces that it was notified on 27 November 2017 that Mary Tavener, who is a Director and PDMR, following the end of the holding period, has exercised 17,207 options from the Deferred Annual Bonus Plan (DAB). Mrs Tavener elected to receive an additional 229 dividend shares which were earned during the 3 year holding period under the terms of the scheme. Mrs Tavener subsequently sold 8,313 Ordinary Shares of 5p each on 27 November 2017 at a share price of 312.109p per Ordinary Share to cover the tax and National Insurance payable on this exercise.
As a result of these transactions Mary Tavener's beneficial interest in the Company has increased from 1,950,568 shares to 1,959,691 shares.
Deferred Annual Bonus Plan (DAB)
Director | DABs prior to exercise | DABs exercised | Dividend Shares received | Ordinary Shares sold | Ordinary Shares retained | DABs after exercise |
Mary Tavener, Chief Financial Officer | 72,935 | 17,207 | 229 | 8,313 | 9,123 | 55,728 |
Overall Holding
Director | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Mary Tavener, Chief Financial Officer | 1,950,568 | 17,207 | 229 | 8,313 | 312.109p | 1,959,691 | 0.92% |
The Company further announces that it was notified on 27 November 2017 that Eddie Johnson, who is a Senior Manager and PDMR, following the successful achievement of certain performance criteria, has exercised 38,450 options from the Long Term Incentive Plan (LTIP). Mr Johnson has also, following the end of the holding period, exercised 3,115 options from the Deferred Annual Bonus Plan (DAB). Mr Johnson elected to receive an additional 41 dividend shares which were earned during the 3 year holding period under the terms of the scheme. Mr Johnson subsequently sold 41,606 Ordinary Shares of 5p each on 27 November 2017 at a share price of 312.109p per Ordinary Share. Following these transactions the beneficial ownership of Eddie Johnson is as follows:
Long Term Incentive Plan (LTIP)
PDMR | No. of LTIPs prior to exercise | LTIPs exercised | LTIPs lapsed | Ordinary Shares sold | Ordinary Shares retained | LTIPs after exercise |
Eddie Johnson | 144,139 | 38,450 | 11,550 | 38,450 | Nil | 94,139 |
Deferred Annual Bonus Plan (DAB)
PDMR | DABs prior to exercise | DABs exercised | Dividend Shares received | Ordinary Shares sold | Ordinary Shares retained | DABs after exercise |
Eddie Johnson | 19,359 | 3,115 | 41 | 3,156 | Nil | 16,244 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Eddie Johnson | 48,734 | 41,565 | 41 | 41,606 | 312.109p | 48,734 | 0.023% |
The Company further announces that it was notified on 27 November 2017 that Pieter van Hoof, who is a Senior Manager and PDMR, following the successful achievement of certain performance criteria, has exercised 38,450 options from the Long Term Incentive Plan (LTIP). Mr van Hoof has also, following the end of the holding period, exercised 2,993 options from the Deferred Annual Bonus Plan (DAB). Mr van Hoof elected to receive an additional 39 dividend shares which were earned during the 3 year holding period under the terms of the scheme. Mr van Hoof has also elected to exercise 38,387 Ordinary Shares of 5p from the Deferred Share Bonus Plan (DSB).
Mr van Hoof subsequently sold 32,810 Ordinary Shares of 5p each on 27 November 2017 at a share price of 312.109p per Ordinary Share to cover the tax and National Insurance payable on this exercise. As a result of these transactions Pieter van Hoof's beneficial interest in the Company has increased from 76,282 shares to 123,341 shares.
Long Term Incentive Plan (LTIP)
PDMR | No. of LTIPs prior to exercise | LTIPs exercised | LTIPs lapsed | Ordinary Shares sold | Ordinary Shares retained | LTIPs after exercise |
Pieter van Hoof | 144,933 | 38,450 | 11,550 | 15,802 | 22,648 | 94,933 |
Deferred Annual Bonus Plan (DAB)
PDMR | DABs prior to exercise | DABs exercised | Dividend Shares received | Ordinary Shares sold | Ordinary Shares retained | DABs after exercise |
Pieter van Hoof | 17,819 | 2,993 | 39 | 1,230 | 1,802 | 14,826 |
Deferred Share Bonus Plan (DSB)
PDMR | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | Ordinary Shares retained | DSBs after exercise |
Pieter van Hoof | 60,057 | 38,387 | 15,778 | 22,609 | 21,670 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Pieter van Hoof | 76,282 | 79,830 | 39 | 32,810 | 312.109p | 123,341 | 0.058% |
The Company further announces that it was notified on 27 November 2017 that Jeff Willis, who is a Senior Manager and PDMR, following the end of the holding period, has exercised 2,437 options from the Deferred Annual Bonus Plan (DAB). Mr Willis elected to receive an additional 32 dividend shares which were earned during the 3 year holding period under the terms of the scheme. Mr Willis has also elected to exercise 5,617 Ordinary Shares of 5p from the Deferred Share Bonus Plan (DSB). Mr Willis subsequently sold 12,512 Ordinary Shares of 5p each on 27 November 2017 at a share price of 312.109p per Ordinary Share. As a result of these transactions Jeff Willis's beneficial interest in the Company has decreased from 165,765 shares to 161,339 shares.
Deferred Annual Bonus Plan (DAB)
PDMR | DABs prior to exercise | DABs exercised | Dividend Shares received | Ordinary Shares sold | Ordinary Shares retained | DABs after exercise |
Jeff Willis | 23,531 | 2,437 | 32 | 2,469 | Nil | 21,094 |
Deferred Share Bonus Plan (DSB)
PDMR | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | Ordinary Shares retained | DSBs after exercise |
Jeff Willis | 31,426 | 5,617 | 5,617 | Nil | 25,809 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Dividend Shares received | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Jeff Willis | 165,765 | 8,054 | 32 | 12,512 | 312.109p | 161,339 | 0.075% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 22,203 shares from the Deferred Annual Bonus Plan · Award of 296 Dividend Shares from the Deferred Annual Bonus Plan · Sale of 10,726 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 10,726 Aggregated price: £3.12109 | ||||
e) | Date of the transaction: 27/11/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Mary Tavener | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 17,207 shares from the Deferred Annual Bonus Plan · Award of 229 Dividend Shares from the Deferred Annual Bonus Plan · Sale of 8,313 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 8,313 Aggregated price: £3.12109 | ||||
e) | Date of the transaction: 27/11/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Eddie Johnson | ||||
2. | Reason for the notification | ||||
a) | Position/status: Senior Manager/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transaction: · Exercise of 38,450 shares from the Long Term Incentive Plan · Exercise of 3,115 shares from the Deferred Annual Bonus Plan · Award of 41 Dividend Shares from the Deferred Annual Bonus Plan · Sale of 41,606 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 41,606 Aggregated price: £3.12109 | ||||
e) | Date of the transaction: 27/11/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Pieter van Hoof | ||||
2. | Reason for the notification | ||||
a) | Position/status: Senior Manager/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 38,450 shares from the Long Term Incentive Plan · Exercise of 2,993 shares from the Deferred Annual Bonus Plan · Award of 39 Dividend Shares from the Deferred Annual Bonus Plan · Exercise of 38,387 shares from the Deferred Share Bonus Plan · Sale of 32,810 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 32,810 Aggregated price: £3.12109 | ||||
e) | Date of the transaction: 27/11/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Jeff Willis | ||||
2. | Reason for the notification | ||||
a) | Position/status: Senior Manager/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 2,437 shares from the Deferred Annual Bonus Plan · Award of 32 Dividend Shares from the Deferred Annual Bonus Plan · Exercise of 5,617 shares from the Deferred Share Bonus Plan · Sale of 12,512 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 12,512 Aggregated price: £3.12109 | ||||
e) | Date of the transaction: 27/11/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Matthew Neal / Philippa Gardner / Rosie Phillips | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Gary Clarence / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.